Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as we know, is associated with coronary artery disease (CAD) approximately in 50% of cases. In high risk surgical patients, this calls for procedures such as percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR).  

Impella

PCI with ventricular assistance devices has surged as a valid option in this scenario; however, we should note that information on this treatment strategy is limited. 

This study recruited 15 patients with severe CAD and severe aortic stenosis at high surgical risk, but the Impella failed to cross the aortic valve in 1 patient, who was excluded despite having received balloon aortic valvuloplasty.   

Mean patient age was 88, and 6 were women. Mortality STS score was 8.3%, and SYNTAX was 16. Also, 12 patients presented hypertension and 3 had diabetes. 

Cardiac parameters showed ejection fraction was 51%, aortic valve area (AVAO) 0.85 cm², and mean gradient 40 mmHg. Left ventricular end-diastolic pressure was 19 mmHg, while median pulmonary capillary wedge pressure was 17 mmHg. Five patients experienced cardiac failure with ventricular function deterioration. 

Read also: Low vs High Dose Drug Coated Balloons in Femoropopliteal Territory.

Left main PCI was performed in 6 patients, rotational atherectomy in 10, and 2 received two-vessel PCI. 

The Impella was advanced via the femoral artery in all patients, which required prior valvuloplasty in two cases. We should point out there were no vascular complications and that the Impella access site was closed with 2 Proglide devices, and the PCI access site was closed with 1 Proglide device. 

As regards complications, there were no significant adverse events after PCI. 

RRead also: Coronary Calcification: More Frequent Use of Coronary Lithotripsy as a Recommendation.

Time between Impella placement and TAVR was 25 days, on average, ranging between 10 and 35 days. 

As regards TAVR, all patients received a Sapien valve successfully, with no serious complications in the 30 days after intervention. 

Conclusion

In sum, the outcomes of this series of cases carried out in a single center indicate that high risk Impella assisted PCI is feasible and safe as preparation for TAVR in selected patients with severe aortic stenosis. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Feasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis. 

Reference: Ilhwan Yeo, el al. JSCAIhttps://doi.org/10.1016/j.jscai.2023.101061.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...